GLP-1 Analogues Market to Reach $471.1 Billion by 2032: A Major Shift in Diabetes Treatment

The global GLP-1 analogues market, valued at US$37.4B in 2023, is forecasted to grow at a 33.2% CAGR, reaching US$47.4B by 2024 and US$471.1B by 2032.
The size of global GLP-1 analogues market in terms of revenue was estimated to be worth $47.4 billion in 2024 and is poised to reach $471.1 billion by 2032, growing at a CAGR of 33.2% from 2024 to 2032. Key drivers include the drugs' efficacy in managing diabetes and obesity, driving high demand and clinical research advancements. The market is dominated by two major players, Novo Nordisk A/S and Eli Lilly and Company, creating significant entry barriers. Opportunities lie in expanding therapeutic applications beyond diabetes to include conditions like NASH and Alzheimer's disease. However, challenges such as patient non-adherence and the dominance of injectable formats hinder market growth. North America leads in market share, supported by accessibility and demand for GLP-1 analogues. Key players like Novo Nordisk, Eli Lilly, Sanofi, and AstraZeneca are pivotal in shaping market dynamics through extensive R&D and strategic expansions.

Download PDF Brochure [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350]

The single dose segment is the fastest-growing of the GLP-1 Analogue market by product format

Based on product format, the global GLP-1 Analogue market is segmented into single-dose, multi-dose, and tablets. In 2023, the single dose segment accounted for the highest growth rate in the GLP-1 Analogue market by product format type. Single dose format is a highly convenient form of the GLP-1 analogs for self-administration as it is increasingly becoming available in the autoinjector form. Additionally, the format is for a lower frequency of administration (majorly once a week). This aids in long term adherence to treatment by patients.

Ozempic (semaglutide) is the largest segment of the GLP-1 Analogues market by product

Based on the products, the global GLP-1 analogues market is segmented into Ozempic (semaglutide), Trulicity (dulaglutide), Mounjaro (tirzepatide), Wegovy (semaglutide), Rybelsus (semaglutide), Saxenda (liraglutide [rDNA origin] injection), Victoza (liraglutide), Xultophy 100/3.6 (insulin degludec and liraglutide injection), Soliqua 100/33 (insulin glargine and lixisenatide injection), Zepbound (tirzepatide), Bydureon (exenatide extended-release), and other products. In 2023, Ozempic (semaglutide) accounted for the largest share of the product segment of the GLP-1 Analogue market. The large share of this market segment can be attributed to the increasing adoption of Ozempic for the treatment of type-2 diabetes. Additionally, the product revenue reveals stable high growth over the years.

Europe: The second-largest region in the GLP-1 Analogue market.

The European market for GLP-1 analogue drugs is the second-largest market globally. The share of this market can be attributed to several key factors. Some of the factors include the strong presence of key market players offering GLP-1 drugs, favorable regulatory scenario and availability of majority of GLP-1 products in the region with reimbursement offered in several countries.

Request Sample Pages [https://www.marketsandmarkets.com/requestsampleNew.asp?id=200829350]

Prominent players in the market are Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), AstraZeneca (UK), and Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (China) among others.

Dominance of Novo Nordisk A/S in the GLP-1 Analogue Market

Novo Nordisk A/S (Denmark) stands as a pivotal force in the GLP-1 Analogue market, boasting a diverse product portfolio highlighted by flagship products like Ozempic and Wegovy. The company's extensive global distribution channels and robust R&D efforts underscore its leadership in insulin and GLP-1 manufacturing worldwide. Novo Nordisk's focus on developing oral formulations of existing GLP-1 drugs further enhances patient convenience and therapeutic efficacy.

Eli Lilly and Company's Strategic Expansion in GLP-1 Analogue Market

Eli Lilly and Company (US) plays a prominent role in advancing the GLP-1 Analogue market, with significant investments exceeding USD 9 billion in R&D during 2023 alone. The company's commercialized products, including Mounjaro, Trulicity, and Zepbound, contribute substantially to its revenue, with Trulicity and Mounjaro jointly accounting for approximately 36% of total earnings in 2023. Eli Lilly's ongoing focus on expanding its clinical pipeline reinforces its competitive position in the market.

Sanofi's Global Presence and Regulatory Advancements

Sanofi (France) maintains a strong foothold in the GLP-1 Analogue market through products like Soliqua, marketed in over 80 countries worldwide. The company's strategic approach includes securing regulatory approvals across diverse geographies, exemplified by recent approvals in China for Soliqua to enhance glycemic control in adults with type 2 diabetes. Sanofi's expansive geographic reach and rigorous regulatory strategies position it as a key player driving market growth and accessibility.

For more information, inquire now! [https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=200829350]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glp1-analogues-market-to-reach-4711-billion-by-2032-a-major-shift-in-diabetes-treatment]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/glp-1-analogues-market-218746186.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.